Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipid Sciences, has reported that Elanco, a division of Eli Lilly and Company, has exercised its right to 'opt in' with a development plan and additional investment on a vaccine study.
Subscribe to our email newsletter
The study is part of a collaborative research and license agreement between Lipid Sciences and Elanco to research immunological products for animal health applications. Lipid Sciences will receive a technology access fee because of Elanco’s decision to move ahead, and might receive payments in the future including milestone payments and royalties from product sales.
Lewis Meyer, president and CEO of Lipid Sciences, said: “We are very pleased by our progress on this vaccine study with Elanco. Our company recently had another win with our Viral Immunotherapy platform – a positive therapeutic effect demonstrated with our delipidated autologous virus vaccine in our HIV program.”